Inclusion Criteria:

- Biopsy proven prostate cancer

- Clinical Tumor Category T1b, T1c, T2a and PSA greater than (>) 10 or Gleason
score equal or greater than 4+3=7 or PSA velocity > 2.0 ng/ml per year and also
eligible patients with tumor category T2c, T3a, T3b, or T4 as per 2002 AJCC
guidelines. Any minor tertiary grade of Gleason 5; Biopsy Proven or Radiographic
(erMRI Seminal Vesicle Invasion); Gleason = or > 3+4=7 with 50% or more cores
positive

- Negative bone scan

- Lymph node assessment by CT or MR

- Adequate hematologic function (Blood Counts)

- Adequate liver functions (blood tests)

- ECOG performance Status 0 or 1

- Peripheral neuropathy must be =< grade 1

- PSA obtained within 3 months of entry

Exclusion Criteria:

- Prior history of malignancy that are < 5 years except for cancers found to be
"in-situ" and would not likely impact a patient's life expectancy with appropriate
medical management.

- Prior pelvic radiation therapy

- Prior hormonal therapy (up to 4 weeks prior to enrollment allowed)

- Individuals unable to tolerate lying still 5 - 10 minutes

- Patients with a history of severe hypersensitivity reaction to docetaxel or other
drugs formulated with polysorbate 90.